AbbVie reported $17.4B in revenue (+10.3% YoY), compared with a +7.2% median across covered Health Care peers. Of 3 tracked management expectations, 2 were consistent with later reports and 0 were contradicted. 1 insider sale recorded. Next scheduled event: Dividend on February 16, 2027.
AbbVie Inc. executives Jeffrey R. Stewart and Azita Saleki-Gerhardt conducted a series of company stock transactions between November 9 and November 16, 2026. The executives exercised stock options and filed notices of proposed sales as part of managing their personal equity holdings.
Companies report on shareholder meeting results, leadership changes, technology updates, and share buyback programs. Below is a summary of key recent events.
AbbVie reported $17.404 billion in net revenue for the third quarter of 2026, a 10.3% increase year-over-year. Diluted earnings per share (EPS) was $2.37 on a GAAP basis, and $3.82 on an adjusted basis. The company raised its full-year adjusted EPS guidance to $13.95–$13.99.
AbbVie said the FDA approved a subcutaneous induction regimen for SKYRIZI for adults with moderately to severely active Crohn's disease. The regimen uses an on-body injector device.
February 16, 2027Dividend $1.73 a share, holders of record on January 15, 2027, paid on February 16, 2027 announcement
As announced by the companies, read by code from their press releases, 8-Ks and official feeds; each date links its announcement. Companies can change dates. Dividends: common shares only; under T+1 settlement the ex-dividend date is normally the record date. Corporate calendar →
Company history
October 2026
AbbVie Inc.: 12 recorded developments from 6 official sources in 2026-10.
2026-09-30: Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity Index.Source
2026-10-05: There can be no assurance that our final results will not differ from these preliminary estimates.Source
2026-10-05: While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions.Source
2026-10-05: Adjusted diluted earnings per share guidance for 2026 previously announced on July 31, 2026 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2026.Source
2026-10-05: Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2026 are expected to include acquired IPR&D and milestones expense of $216 million on a pre-tax basis, representing an unfavorable impact of $0.11 to both GAAP diluted earnings per share and adjusted non-GAAP Source
2026-10-05: Results for the quarter ended September 30, 2026 have not been finalized and are subject to our financial statement closing procedures.Source
2026-10-11: New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpointsSource
2026-10-13: AbbVie presented new Phase 3 AFFIRM data showing clinical and endoscopic outcomes with subcutaneous SKYRIZI in patients with moderately to severely active Crohn's disease.Source
2026-10-15: On October 14, 2026, AbbVie Inc. expanded its Board of Directors from twelve to thirteen directors and appointed Dr. John M. Carethers as a Class II director.Source
2026-10-15: Dr. John M. Carethers was appointed to the Public Policy and Sustainability Committee of AbbVie.Source
2026-10-15: The Board affirmatively determined that Dr. John M. Carethers is an independent director under NYSE standards and AbbVie's guidelines.Source
2026-10-30: AbbVie Inc. issued a press release on October 30, 2026, announcing financial results for the third quarter ended September 30, 2026.Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Key figures
From the 10-Q for the period ended September 30, 2026, filed November 3, 2026. SEC
Latest
Earlier
Change
Revenue quarter
$17.4B
$15.8B
+10.3%
Operating income quarter
$6.3B
$1.9B
+229.1%
Net income quarter
$4.2B
$186M
+2,167.7%
Diluted EPS quarter
$2.37
$0.10
+2,270.0%
Dividends per share quarter
$1.73
$1.64
+5.5%
Operating cash flow year to date
$14.9B
$13.8B
+7.7%
Cash and cash equivalents balance
$10.8B
$5.2B
+106.0%
Next results expected around February 2, 2027 (estimate: the quarter ending about December 30, 2026 plus the 34 days the last report took). The company announces the actual date.
As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV
Revenue by quarter, $B
Bottom row: operating margin (operating income divided by revenue). Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
AI assessment, provisional later reports are consistent with it (as of November 16, 2026) · Later article
Open
Regulatory submissions for lutikizumab in HS are expected.
Said October 30, 2026 · Period named: second half of 2027 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
Date
Event
Filing
November 2, 2026
Director or officer departure or appointment (8-K item 5.02)
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.